Learning from Prozac: A Case Study on Reforming the FDA Drug Approval Process

DSpace/Manakin Repository

Learning from Prozac: A Case Study on Reforming the FDA Drug Approval Process

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Wood, Maria en_US
dc.date.accessioned 2012-06-07T05:36:50Z
dc.date.issued 1997 en_US
dc.identifier.citation Learning from Prozac: A Case Study on Reforming the FDA Drug Approval Process (1997 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8846814
dc.description.abstract The law, focused as it is on making final determinations and settling issues one way or another, continually lags behind science, which concentrates on an evolving understanding of various phenomena through constant enhancement of current understandings of existing realities. Thus, a drug approval process, which obviously deals with scientific issues of drug development, cannot always keep pace with scientific understandings of drug development. The law is flexible and capable of accommodating new understandings, though; therefore, consideration of the scientific issues involved in drug development and approval is appropriate and ought to be undertaken as much as possible in order to develop legal answers that are as accurate as they can be at any given time. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject prozac en
dc.subject regulatory reform en
dc.subject prescription drug licensure en
dc.subject human drugs en
dc.subject FDA approval process en
dc.title Learning from Prozac: A Case Study on Reforming the FDA Drug Approval Process en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-07T05:36:50Z

Files in this item

Files Size Format View
mwood.pdf 567.0Kb PDF View/Open
mwood.rtf 286.7Kb RTF file View/Open
mwood.html 215.8Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters